An interventional study of Morcher iris diaphragm implantation in Aniridia and Iris; Deformity, sponsored by University of California, Los Angeles. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-15.
Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment
The purpose of this study is to determine the safety and efficacy of Morcher iris diaphragms in the treatment of congenital and acquired aniridia. Morcher iris diaphragms are intraocular devices that are designed to provide an artificial pupil for patients suffering from partial or complete aniridia. These devices are constructed from clinical quality, ultraviolet light-absorbing, opaque black polymethylmethacrylate (PMMA). After surgical implantation, patients are monitored over the course of 1 year to measure any changes to visual acuity and improvements in light and glare sensitivity.
Aniridia is a condition in which the iris, the colored portion of the eye, is either partially or completely absent. The iris is responsible for regulating the amount of light entering the eye by adjusting the size of the pupil.
Aniridia can either be a congenital condition, often a genetically-based abnormality affecting the formation of the iris, or it can be acquired by blunt trauma with or without rupture, penetrating trauma, or severe intraocular inflammation.
Aniridia can also vary in the level of severity. A mild case might involve a thinner iris or iris remnant with a normal pupil. A severe case might involve complete absence of the iris or impairment of the muscles responsible for adjusting pupil size.
Iris defects can occur without the loss of stromal tissue as well. In some cases, the iris pigment epithelium is missing. In other cases, holes are present in the iris or the pupil is chronically enlarged or mydriatic.
People who suffer from iris defects also commonly suffer from other eye conditions. Common comorbidities include glaucoma, cataract, and nystagmus. Other structures in the eye are often affected, including the cornea, crystalline lens, zonules, and retina. Iris defects can cause severe visual disability if untreated.
Common treatments for iris defects include the use of colored or tinted glasses or contact lenses to reduce the amount of light entering the eye.
In this trial, several Morcher iris diaphragms are being evaluated as a potential treatment to improve the symptoms associated with aniridia and other iris defects. Morcher iris diaphragms are manufactured in Germany by Morcher GmbH [website: http:// www.morcher.com]. These devices have been utilized in Europe to treat aniridic patients for over 40 years. Additionally, these devices hold the European CE mark of conformity.
When a patient is implanted with a Morcher iris device, surgery always involves additional standard of care surgical procedures. Typically, a device is implanted during cataract surgery along with an intraocular lens (IOL). Morcher devices can also be implanted during an IOL exchange with or without an anterior vitrectomy. All implantation procedures take place in an operating room under local or general anesthesia. In some cases, a Morcher iris reconstruction lens containing both an artificial iris and a lens is implanted. Also, depending on the condition of the eye, the lens and iris device may need to be sutured to the sclera, the white portion of the eye.
All patients undergoing surgery are prescribed 2 different eye drops, an antibiotic and a corticosteroid. These medications are used for up to 6 weeks following implantation of the device. There are 5 postoperative follow-up visits that each patient must complete. Visits occur at specific intervals over the course of a 1-year period. At each visit, standard of care procedures are performed and, at certain time points during the follow-up interval, digital photos and endothelial cell counts are obtained. In instances where both eyes are implanted, surgery for the second eye is scheduled 6 months or more later.
23 studies on the registry are indexed under Aniridia; 8 are open to participants now.
Browse Aniridia studies →University of California, Los Angeles is the lead sponsor of 1,142 studies on the registry; 192 are open to participants now.
Of its 91 completed or terminated interventional studies of FDA-regulated products, 66 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
This is a non-randomized, non-comparative interventional surgical series. Patients will undergo Morcher iris diaphragm implantation in their affected eye(s). After surgery, patients will complete 5 postoperative examinations. At each examination, they will be evaluated for changes in light and glare sensitivity and visual acuity. They will also be monitored for adverse reactions.
Device: Morcher iris diaphragm implantation
Surgical implantation of Morcher iris device(s)
Also known as: Morcher device models: 96F, 96S, 50D, 50F, and 67B
Change in Light and Glare Sensitivity as Determined by a Clinical Glare Test (Primary Efficacy Measure)
The primary efficacy measure of the study was the change in corrected distance visual acuity (CDVA) under glare conditions. A transilluminator light was held just in front of the distance corrected study eye in one of four quadrants (above, below, nasal, or temporal) to the line of sight to evoke a glare response. The direction that produced the worst CDVA was called the CDVA with glare. A ≥ 2 line improvement in Snellen CDVA with glare following Morcher device implantation was considered a positive clinical change (glare sensitivity better). A ≥ 2 line worsening of Snellen CDVA with glare following Morcher device implantation was considered a negative clinical change (glare sensitivity worse). A change of \< 2 Snellen lines following Morcher device implantation was considered to be a neutral change (glare sensitivity the same).
Time frame: Preoperatively and 1 year postoperatively
Change in Best Corrected Visual Acuity (Primary Safety Measure)
The primary safety measure of the study was the change in best corrected distance visual acuity (CDVA) as measured using a Snellen eye chart. A ≥ 2 line improvement in Snellen CDVA following Morcher device implantation was considered a positive clinical change (visual acuity better). A ≥ 2 line worsening of Snellen CDVA following Morcher device implantation was considered a negative clinical change (visual acuity worse). A change of \< 2 lines was considered to be a neutral change (visual acuity the same).
Time frame: Preoperatively and 1 year postoperatively
Change in Glare Sensitivity Under Day Time Lighting Conditions (Secondary Efficacy Measure)
A secondary efficacy measure of the study was day time glare disability as assessed by subjective questionnaire. Glare disability was rated using a 0 to 10 scale, where 0 was considered very slight and 10 was considered very significant.
Time frame: Preoperatively and 3 months postoperatively
Change in Glare Sensitivity Under Night Time Lighting Conditions (Secondary Efficacy Measure)
Another secondary efficacy measure of the study was night time glare disability as assessed by subjective questionnaire. Glare disability was rated using a 0 to 10 scale, where 0 was considered very slight and 10 was considered very significant.
Time frame: Preoperatively and 3 months postoperatively
Change in Endothelial Cell Count (Secondary Safety Measure)
A secondary safety measure of the study was the change in endothelial cell count. A loss of \>10% of central corneal endothelial cells was considered clinically significant at the onset of the study. (Note, the 10% loss criterion was established before the 67B implant was added to the list of study devices. The 67B implant has an expected greater cell loss than that associated with the 96F, 96S, 50D, and 50F modified capsule tension rings because it requires a larger incision for implantation. Thirty one (48.4%) of the 64 patients were implanted with the 67B device.)
Time frame: Preoperatively and 3 months postoperatively
Need to Explant or Exchange a Morcher Iris Diaphragm (Secondary Safety Measure)
Another secondary safety measure of the study was the need to explant or exchange a Morcher iris diaphragm within 1 year of implantation. Explantation in \< 25% of patients was considered to be clinically acceptable.
Time frame: Preoperatively and 1 year postoperatively
Most patients were recruited from the principal investigator's ophthalmic practice. A few were referred by local ophthalmologists.
| Milestone | Morcher Iris Diaphragm Study Group |
|---|---|
| Started | 72 |
| Taken to surgery for device implantation | 66 |
| Completed | 64 |
| Not completed | 8 |
| Withdrew: Device could not be implanted | 2 |
| Withdrew: Lack of medical insurance | 1 |
| Withdrew: Switched to another study | 1 |
| Withdrew: Surgery cancelled due to uveitis | 1 |
| Withdrew: Signed consent but later withdrew | 3 |
The primary efficacy measure of the study was the change in corrected distance visual acuity (CDVA) under glare conditions. A transilluminator light was held just in front of the distance corrected study eye in one of four quadrants (above, below, nasal, or temporal) to the line of sight to evoke a glare response. The direction that produced the worst CDVA was called the CDVA with glare. A ≥ 2 line improvement in Snellen CDVA with glare following Morcher device implantation was considered a positive clinical change (glare sensitivity better). A ≥ 2 line worsening of Snellen CDVA with glare following Morcher device implantation was considered a negative clinical change (glare sensitivity worse). A change of \< 2 Snellen lines following Morcher device implantation was considered to be a neutral change (glare sensitivity the same).
| Participants | Morcher Iris Diaphragm Implantation Group |
|---|---|
| Glare sensitivity better | 51 |
| Glare sensitivity the same | 12 |
| Glare sensitivity worse | 1 |
The primary safety measure of the study was the change in best corrected distance visual acuity (CDVA) as measured using a Snellen eye chart. A ≥ 2 line improvement in Snellen CDVA following Morcher device implantation was considered a positive clinical change (visual acuity better). A ≥ 2 line worsening of Snellen CDVA following Morcher device implantation was considered a negative clinical change (visual acuity worse). A change of \< 2 lines was considered to be a neutral change (visual acuity the same).
| Participants | Morcher Iris Diaphragm Implantation Group |
|---|---|
| Visual acuity better | 35 |
| Visual acuity the same | 28 |
| Visual acuity worse | 1 |
A secondary efficacy measure of the study was day time glare disability as assessed by subjective questionnaire. Glare disability was rated using a 0 to 10 scale, where 0 was considered very slight and 10 was considered very significant.
| Participants | Morcher Iris Diaphragm Implantation Group |
|---|---|
| Subjective day time glare sensitivity better | 57 |
| Subjective day time glare sensitivity the same | 5 |
| Subjective day time glare sensitivity worse | 2 |
Another secondary efficacy measure of the study was night time glare disability as assessed by subjective questionnaire. Glare disability was rated using a 0 to 10 scale, where 0 was considered very slight and 10 was considered very significant.
| Participants | Morcher Iris Diaphragm Implantation Group |
|---|---|
| Subjective night time glare sensitivity better | 56 |
| Subjective night time glare sensitivity the same | 5 |
| Subjective night time glare sensitivity worse | 3 |
A secondary safety measure of the study was the change in endothelial cell count. A loss of \>10% of central corneal endothelial cells was considered clinically significant at the onset of the study. (Note, the 10% loss criterion was established before the 67B implant was added to the list of study devices. The 67B implant has an expected greater cell loss than that associated with the 96F, 96S, 50D, and 50F modified capsule tension rings because it requires a larger incision for implantation. Thirty one (48.4%) of the 64 patients were implanted with the 67B device.)
| Participants | Morcher Iris Diaphragm Implantation Group |
|---|---|
| Endothelial cell loss ≤ 10% | 17 |
| Endothelial cell loss > 10% | 18 |
Another secondary safety measure of the study was the need to explant or exchange a Morcher iris diaphragm within 1 year of implantation. Explantation in \< 25% of patients was considered to be clinically acceptable.
| Participants | Morcher Iris Diaphragm Implantation Group |
|---|---|
| Morcher device explanted | 1 |
| Morcher device not explanted | 63 |
Collected over Adverse event data were collected for 1 year following Morcher iris diaphragm implantation.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Morcher Iris Diaphragm Implantation Group | 0/64 (0%) | 6/64 (9.4%) | 5/64 (7.8%) |
| Event | Morcher Iris Diaphragm Implantation Group |
|---|---|
| Decentered piggyback intraocular lensEye disorders | 1/64 |
| Retained lens fragmentEye disorders | 1/64 |
| Corneal failureEye disorders | 1/64 |
| Corneal graft-host interface leakEye disorders | 1/64 |
| Morcher iris diaphragm rotationEye disorders | 1/64 |
| Retinal detachmentEye disorders | 1/64 |
| Event | Morcher Iris Diaphragm Implantation Group |
|---|---|
| Ocular hypertensionEye disorders | 2/64 |
| Intraoperative hyphemaEye disorders | 1/64 |
| Cystoid macular edemaEye disorders | 1/64 |
| Acute iritisEye disorders | 1/64 |
One eye per patient was enrolled, thus the number of study eyes equals the number of study participants.
| Age, Categorical(Participants) | Morcher Iris Diaphragm Study Group |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 47 |
| >=65 years | 25 |
| Sex: Female, Male(Participants) | Morcher Iris Diaphragm Study Group |
|---|---|
| Female | 21 |
| Male | 51 |
| Race (NIH/OMB)(Participants) | Morcher Iris Diaphragm Study Group |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 8 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 47 |
| More than one race | 0 |
| Unknown or Not Reported | 15 |
| Region of Enrollment(Participants) | Morcher Iris Diaphragm Study Group |
|---|---|
| United States | 72 |
Plan to share: No
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Los Angeles